Irbesartan/Hydrochlorthiazid Medical Valley

Irbesartan, the active ingredient in Irbesartan/Hydrochlorothiazide Medical Valley, is an angiotensin II receptor blocker presented as a combination tablet for oral use. It treats hypertension, often in adults who need additional blood‑pressure control.

GNH USA supplies Irbesartan/Hydrochlorothiazide Medical Valley as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Irbesartan/Hydrochlorothiazide is used to manage hypertension, a condition characterized by elevated arterial pressure.

Hypertension: lowers systolic and diastolic blood pressure and reduces the risk of cardiovascular complications.

Common Side Effects: - Dizziness or light‑headedness - Headache - Fatigue or weakness - Increased urination - Electrolyte disturbances (e.g., low potassium) - Mild gastrointestinal discomfort

Serious or Rare Side Effects: - Severe dehydration or electrolyte imbalance - Acute kidney injury or worsening renal function - Hyperkalemia, especially when combined with potassium‑sparing agents - Angioedema or severe allergic reaction - Significant drops in blood pressure (hypotension) - Hepatic dysfunction or jaundice

Irbesartan/Hydrochlorothiazide should be used with careful clinical monitoring. - Blood Pressure Monitoring: check regularly to avoid hypotension. - Renal Function: assess serum creatinine and eGFR before and during therapy. - Electrolyte Balance: monitor potassium and sodium levels, especially in patients on other diuretics. - Elderly Patients: start at lower doses and watch for orthostatic symptoms. - Pregnancy and Breastfeeding: avoid use unless benefits clearly outweigh risks. - Store at ambient temperature: keep in original container, protect from moisture and direct sunlight.

Irbesartan/Hydrochlorothiazide may interact with several medicines.

Major Interactions (Avoid): - Aliskiren in patients with diabetes or renal impairment - Lithium: increased lithium levels and toxicity risk - Potassium‑sparing diuretics or supplements: risk of hyperkalemia - ACE inhibitors or other ARBs: additive effect on potassium and renal function - NSAIDs: may reduce antihypertensive efficacy and affect renal function

Moderate Interactions (Monitor Closely): - Other antihypertensives: may enhance blood‑pressure lowering effect - CYP3A4 inhibitors (e.g., ketoconazole): can increase irbesartan exposure - Antidiabetic agents: diuretic‑induced changes in glucose control - Loop diuretics: additive diuretic effect, monitor volume status - Antacids containing aluminum or magnesium: may affect absorption of hydrochlorothiazide